期刊文献+

甲减性心脏病患者血清促甲状腺激素受体抗体、抗甲状腺过氧化物酶抗体水平的变化 被引量:7

下载PDF
导出
摘要 目的研究甲状腺功能减退性心脏病患者血清促甲状腺激素受体(TR)、抗甲状腺过氧化物酶(TPO)抗体水平的变化。方法甲减心脏病患者60例,根据患者肌酸激酶(CK)及其同工酶(CKMB)、乳酸脱氢酶(LDH)等水平分两组,即心肌酶谱正常组、心肌酶谱升高组。观察患者TR、TPO抗体水平变化,分析甲减性心脏病患者TR、TPO抗体水平变化及其与心肌酶谱的相关性。结果与心肌酶谱正常者相比,心肌酶谱升高组患者血清TR、TPO抗体水平明显升高(P<0.05),直线相关分析显示TR、TPO抗体与各心肌酶呈正相关(P<0.05)。结论甲减性心脏病患者TR、TPO抗体水平明显增高,且与心肌损伤程度呈正相关。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第14期2938-2940,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献11

  • 1Downs H, Meyer AA, Flake D, et al. Clinical inquiries : how useful are au- toantibodies in diagnosing thyroid disorders [ J ] ? J Fam Pract, 2008 ; 57 (9) :615-6.
  • 2兰玲,施秉银.促甲状腺素受体抗体检测的临床意义[J].国外医学(内分泌学分册),2005,25(1):42-44. 被引量:12
  • 3Effraimidis G, Tijssen JG, Wiersinga WM. Discontinuation of smoking in- creases the risk for developing thyroid peroxidase antibodies and/or thyro- globulin antibodies: a prospective study [ J]. J Clin Endocrinol Metab, 2009;94(4) :1324-8.
  • 4Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults[ J]. JAMA ,2006 ;295 (9) : 1033-41.
  • 5Schmidt-Ott UM, Ascheim DD. Thyroid hormone and heart failure [J]. Curr Heart Fail Rep,2006;3(3) :114-9.
  • 6Shuvy M, Shifman OE, Nusair S, et al. Hypothyroidism-induced myocardi- al damage and heart failure:an overlooked entity [ J ]. Cardiovasc Pathol, 2009;18(3) :183-6.
  • 7Ness-Abramof R, Nabriski DA, Shapiro MS, et al. Cardiac troponin T is not increased in patients with hypothyroidism[ J]. Intern Med J,2009 ;39 (2) :117-20.
  • 8张红,吕述军,陆卫平,高鹏霞,胡长军,刘影.甲状腺素对原发性甲减患者心肌酶谱、血脂的影响[J].中国老年学杂志,2010,30(5):694-695. 被引量:10
  • 9Hekimsoy Z, Oktem IK. Serum creatine kinase levels in overt and subclin- ical hypothyroidism [ J ]. Endocr Res,2005 ;31 (3) : 171-5.
  • 10杨士军,谭维琴,刘满庆.TGA、TPOAb、TRAb测定对甲状腺疾病的诊断价值[J].放射免疫学杂志,2008,21(4):321-322. 被引量:20

二级参考文献33

  • 1徐华,高燕燕,关建民,黄志宏,姜冬青,赵家军.原发性甲减患者左旋甲状腺素治疗后血脂、心肌酶谱及体成分的变化[J].中华内分泌代谢杂志,2005,21(2):110-113. 被引量:46
  • 2Bobadilla I, Franco M, Cruz D, et al. Hypothyroidism provides resistance to reperfusion injury following myocardium ischemia [ J]. Int J Biochem Cell Biol,2001 ;33:499-506.
  • 3Duntas LH. Thyroid disease and lipids[ J]. Thyroid ,2002 ; 12:287-93.
  • 4Klein I,Ojamma K. Thyroid hormone-targeting the heat [ J ]. Endocrinology,2001 ;142:11.
  • 5Diekman T, Demacker PN, Kastelein J J, et al. Increased oxidizability of low-density lipoproteins in hypothyroidism[J]. J Clin Endocrinol Metab, 1998 ;83:1752-5.
  • 6Sasaki S, Kawai K, Honjo Y, et al. Thyroid hormones and lipid metabolism[J]. Nippon Rinsho ,2006 ;64:2323-9.
  • 7Duntas LH, Wartofsky L Cardiovascular risk and subclinical hypothyroidism:focus on lipids and new emerging risk factors. What is the evidence[J]. Thyroid ,2007 ; 17 : 1075-84.
  • 8Kashiwai T, Hidaka Y, Takano T, et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J, 2003,50:45-49.
  • 9Wallaschofski H, Miehle K, Mayer A, et al. Prediction of remission or relapse for Graves' hyperthyroidism bythe combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Res, 2002, 34:383-388.
  • 10Lugate M, Baker G. Unlocking the mechanisms of orbital inflammation in the thyroid eye disease. Clin Exp Immunol,2002,127:193-198.

共引文献53

同被引文献55

引证文献7

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部